Toll-like receptor 2: therapeutic target for gastric carcinogenesis

William McCormack, Masanobu Oshima, Patrick Tan, Brendan John Jenkins

Research output: Contribution to journalLetterOther

6 Citations (Scopus)


Our recent study suggests that at least in the context of gastric cancer, TLR2 antagonists can ameliorate tumour growth by acting directly on the tumour cells to promote apoptosis and suppress proliferation. However, it is important to consider that TLR agonists (including those for TLR2) can induce adaptive immune responses against cancer cells, which supports the application of TLR agonists in cancer vaccine therapy.
Original languageEnglish
Pages (from-to)1260 - 1261
Number of pages2
Issue number11
Publication statusPublished - 2012

Cite this